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OBJECTIVES The goal of this study was to determine if the haptoglobin phenotype was predictive of
cardiovascular disease (CVD) in diabetic mellitus (DM).
BACKGROUND Cardiovascular disease is the most frequent, severe, and costly complication of type 2 DM.
There are clear geographic and ethnic differences in the risk of CVD among diabetic patients
that cannot be fully explained by differences in conventional CVD risk factors. We have
demonstrated that a functional allelic polymorphism in the haptoglobin gene acts as a major
determinant of susceptibility for the development of diabetic microvascular complications.
METHODS We sought to determine if this paradigm concerning the haptoglobin gene could be extended
to CVD in DM. We tested this hypothesis in a case-control sample from the Strong Heart
study, a population-based longitudinal study of CVD in American Indians. Haptoglobin
phenotype was determined by polyacrylamide gel electrophoresis in 206 CVD cases and 206
matched controls age 45 to 74 years. Median follow-up was six years.
RESULTS In multivariate analyses controlling for conventional CVD risk factors, haptoglobin pheno-
type was a highly statistically significant, independent predictor of CVD in DM. The odds
ratio of having CVD in DM with the haptoglobin 2-2 phenotype was 5.0 times greater than
in DM with the haptoglobin 1-1 phenotype (p  0.002). An intermediate risk of CVD was
associated with the haptoglobin 2-1 phenotype.
CONCLUSIONS This study suggests that determination of haptoglobin phenotype may contribute to the
algorithm used in CVD risk stratification, and in evaluation of new therapies to prevent CVD
in the diabetic patient. (J Am Coll Cardiol 2002;40:1984–90) © 2002 by the American
College of Cardiology Foundation
Cardiovascular disease (CVD) is the most frequent, severe,
and costly complication of type 2 diabetes mellitus (DM)
(1). It is the leading cause of death among patients with type
2 DM regardless of DM duration (2). Population-based
studies have shown that the relative risk of CVD in DM is
several fold higher compared with those without DM (3).
This increased risk appears to be even more striking in
women (3). Risk factors such as hypertension, hyperlipid-
emia, and cigarette smoking independently increase the risk
to the DM patient of developing CVD, but the effect of
DM appears to be independent of conventional risk factors
(3).
Although the incidence of CVD is higher in DM
compared with non-DM in all populations studied, there
are geographic and ethnic differences in the risk of CVD
among DM patients that cannot be fully explained by
differences in conventional CVD risk factors between these
groups (4). These studies suggest that genetic factors could
contribute to differences in susceptibility to CVD among
individuals with DM. One such factor is a functional allelic
polymorphism in the haptoglobin gene. In man, there are
two general classes of alleles for the haptoglobin gene,
designated 1 and 2 (5,6). The haptoglobin 2 allele appears to
have arisen from the 1 allele early in human evolution and to
have spread in the world population as a result of selective
pressures related to resistance to infectious agents (7,8).
Haptoglobin alleles differ dramatically in their relative
frequency among different ethnic groups (9). The protein
products of the two haptoglobin alleles differ both in
biophysical and biochemical properties. A key difference
between the alleles is that the protein product of the 1 allele
is a more potent antioxidant compared with that produced
by the 2 allele (10).
We have demonstrated that haptoglobin phenotype is
predictive of development of microvascular complications in
DM (11–13). Specifically, we have shown that patients who
are homozygous for the haptoglobin 1 allele are at decreased
risk for developing retinopathy and nephropathy. This
effect, at least for nephropathy, has been observed in both
type 1 and type 2 DM and the relevance strengthened by the
finding of a gradient effect with respect to the number of
haptoglobin 2 alleles and the development of nephropathy
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(13). Furthermore, the haptoglobin phenotype may be
predictive of development of macrovascular complications
in DM. We have shown that development of restenosis after
percutaneous coronary angioplasty is significantly decreased
in DM patients with the 1-1 haptoglobin phenotype (11–
14). Previous retrospective and cross-sectional studies ex-
amining haptoglobin phenotype and coronary artery disease
in the general population have yielded conflicting results
(15–17). The role of haptoglobin phenotype in the devel-
opment of atherosclerotic coronary artery disease in DM has
not been studied.
American Indians, previously thought to be resistant to
developing coronary artery disease, are presently experienc-
ing CVD in epidemic proportions (18). The increased
incidence of CVD has been attributed to the sharp increase
in type 2 DM in this population (1,2). The Strong Heart
Study (SHS) has examined the incidence, prevalence, and
risk factors of CVD in American Indian populations in
three geographic areas since 1988 with continued surveil-
lance to the present time (18). The relative genetic homo-
geneity of this population, along with the high prevalence of
DM, permits a unique opportunity for identification of
genetic factors that may contribute to CVD in DM.
Accordingly, we aimed to determine the relative risk of
CVD in DM according to haptoglobin phenotype in a
case-control sample from the SHS.
METHODS
Detailed descriptions of the SHS study design, survey
methods, and laboratory techniques and the participating
Indian communities have been published (18–20). All SHS
participants gave consent for utilization of their blood
samples in genetic studies. In addition, institutional review
boards of individual tribes and of the tribal communities
approved use of stored blood samples for the determination
of haptoglobin phenotype.
The SHS study cohort consists of 4,549 individuals ages
45 to 74 years who were seen at the first examination
conducted between July, 1989 and January, 1992. Partici-
pation rates of all eligible tribe members averaged 64%.
Nonparticipants were similar to participants in age and
self-reported frequency of DM. Reexamination rates for
those alive at the second examination (July 1993 to Decem-
ber 1995) averaged 89% and at the third examination (July
1997 to December 1999) averaged 88%. However, surveil-
lance for cardiovascular events by review of hospital records
and tribal records was also performed on participants who
did not attend the second and third examinations such that
greater than 99% of all cardiovascular events occurring in
the SHS cohort were detected (20).
Blood samples were collected in the presence of EDTA,
and the plasma was stored at 80°C. Standardized blood
pressure (BP) measurements were obtained, and electrocar-
diograms were recorded and coded as previously described
(19,20). Participants were classified as diabetic according to
WHO criteria (21).
Deaths in the SHS cohort between 1988 and the present
were identified through tribal and hospital records and by
direct contact by study personnel with participants and their
families. Copies of death certificates were obtained from
state health departments and ICD-9 coded centrally by a
nosologist. Possible CVD deaths were initially identified
from death certificates as described previously (22). Cause of
death was investigated through autopsy reports, medical
records abstractions, and informant interviews as described
previously (22).
Medical records were reviewed at each examination to
identify nonfatal cardiovascular events, definite myocardial
infarction, and definite CVD (18,23) that had occurred
since the previous examination. Records of those who did
not participate in the second or third examination were also
reviewed to maximize event ascertainment. For all potential
CVD events or interventions, medical records were re-
viewed by trained medical record abstractors. Blinded re-
view of abstracted records by other physician members of
the Morbidity Review Committee showed 90% concor-
dance in diagnosis.
Definition of case-control sample. This case-control
sample was designed to examine the relationship between
CVD and haptoglobin phenotype. A total of 206 CVD
cases and 206 controls (matched for age, gender, and
geographic area) were included in the analysis. Incident
cases of fatal and nonfatal CVD were ascertained during
ongoing surveillance between 1989 and 1998 (18). Cases in
this report consisted of one-half of all CVD cases identified
during this surveillance period. These cases were selected at
random. Controls were selected at random from all age,
gender, and center-matched individuals without CVD at
the time of case ascertainment.
Haptoglobin phenotyping. The haptoglobin gene on
chromosome 16 exists as two allelic variants (5,6). The
haptoglobin phenotype refers to the distinct set of polymeric
haptoglobin molecules produced from the two classes of
haptoglobin alleles. The polymeric nature of the haptoglo-
bin molecule (dimer, linear, or cyclic polymer) is dependent
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on the haptoglobin alleles because the protein product of the
1 allele is monovalent, combining with only one other
haptoglobin monomer, while the protein product of the 2
allele is bivalent, combining with two other haptoglobin
monomers (6). A signature pattern of polymeric species is,
therefore, obtained from individuals who are homozygous
for the 1 allele (Hp 1-1), homozygous for the 2 allele (Hp
2-2), or are heterozygous at the haptoglobin locus (Hp 2-1).
This unique pattern of polymeric species first demonstrated
over 45 years ago by Smithies (24) by gel electrophoresis
remains the most common method used today for phenotyp-
ing haptoglobin. Accordingly, we phenotyped haptoglobin
from 10 l of plasma by polyacrylamide gel electrophoresis
according to established methods (25). Haptoglobin pheno-
typing was performed without knowledge concerning partici-
pant case/control status. Because diabetes is associated with
posttranslational modification of serum proteins, there was
concern whether the haptoglobin phenotype of diabetic
patients would accurately reflect the correct haptoglobin
allele. We observed the same three unambiguous banding
patterns in nondiabetic and diabetic patients. Furthermore,
proof of coincidence in diabetic patients of the haptoglobin
phenotype and the haptoglobin genotype was demonstrated
by 100% concordance in over 300 diabetic and nondiabetic
patients in which we have typed haptoglobin both from the
plasma and from DNA by polymerase chain reaction.
Statistical analysis. Cardiovascular disease risk factors in-
cluding age, gender, low-density lipoprotein (LDL) choles-
terol, high-density lipoprotein (HDL) cholesterol, triglyc-
erides, systolic BP, body mass index (BMI), diabetes,
smoking status, family history of CVD, and geographic area
were compared between cases and controls as well as
between the three haptoglobin phenotypes. In addition,
DM-associated characteristics including fasting glucose and
insulin levels, HbA1c, DM duration, and family history of
DM were compared between cases and controls as well as
between the three haptoglobin phenotypes. Univariate and
multinomial logistic regression modeling was performed to
determine if these CVD risk factors and DM characteristics
were related to phenotype. The likelihood ratio test was
used to evaluate individual model parameters.
Consistent with the case-control design, conditional lo-
gistic regression was used to model the probability of having
a CVD event for diabetic and nondiabetic patients by the
three haptoglobin phenotypes. A diabetes-haptoglobin phe-
notype interaction term was coded using two indicator
variables, one for patients with diabetes and another for
patients without diabetes. Nested models were constructed,
first with only the DM-haptoglobin variables, then adjusted
for DM characteristics (fasting glucose and insulin levels,
HbA1c, and family history of DM), and then for DM
characteristics and CVD risk factors (LDL cholesterol,
HDL cholesterol, triglycerides, systolic BP, BMI, smoking
status, and family history of CVD). Adjustment was de-
signed to account for known and postulated biological
relationships among specific factors in the disease pathway.
Adjustment for known CVD risk factors in the presence of
haptoglobin permits testing of the hypothesis that hapto-
globin is related to CVD independently of known CVD risk
factors, and whether this relationship is similar in diabetic
and nondiabetic participants. Model fit was assessed by an
analysis of residuals. We report odds ratios and 95%
confidence intervals (CI) for the probability of a CVD event
for each haptoglobin phenotype in diabetic and nondiabetic
individuals.
RESULTS
Table 1 shows the clinical characteristics of the case-control
sample according to CVD risk factors and DM character-
istics. Cases and controls were matched for age, gender, and
geographic area. These data are consistent with our previous
finding in this population that DM, LDL cholesterol,
triglycerides, and hypertension are all independent predic-
tors of CVD (18).
The distribution of the haptoglobin phenotypes accord-
ing to case-control and DM status is shown in Table 2. The
distribution of the haptoglobin phenotypes in the case-
control sample was consistent with the Hardy-Weinberg
expectation (p  0.98). We found no significant difference
between the haptoglobin phenotypes for any of the CVD
risk factors or DM characteristics as determined both by
univariate analysis and by multinomial logistic regression
analysis. There was no significant difference in the duration
of DM between the haptoglobin phenotypes.
Table 3 shows conditional logistic regression analysis of
the odds of CVD for each of the haptoglobin phenotypes in
DM and non-DM individuals before and after adjustment
for DM characteristics and CVD risk factors. After adjust-
ment for DM characteristics and CVD risk factors, partic-
ipants with DM and an Hp 2-2 phenotype were 4.96 (95%
CI, 1.85 to 13.33) times more likely to have had a CVD
event than those with DM and an Hp 1-1 phenotype (p 
0.002) and 3.04 (95% CI, 1.30 to 7.09) times more likely to
have had a CVD event than those with DM and an Hp 2-1
phenotype (p  0.010). Moreover, participants with DM
and an Hp 2-1 phenotype were 1.63 (95% CI, 0.74 to 3.63)
times more likely to have had a CVD event than those with
DM and a Hp 1-1 phenotype although this was not
statistically significant. This analysis was also performed
including only cases and controls with diabetes, and the
results were the same although the CIs were wider. Taken
together, these data suggest a graded risk associated with the
number of haptoglobin 2 alleles on development of CVD in
DM that is independent of conventional CVD risk factors
and DM characteristics. Finally, in patients without DM,
we observed a trend of borderline statistical significance
showing that the non-DM patients with a haptoglobin
phenotype of 2-2 were 2.73 (95% CI, 0.81 to 9.26) times
more likely to have had a CVD event than non-DM with a
1-1 haptoglobin phenotype (p  0.107).
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DISCUSSION
This case-control study demonstrates that haptoglobin phe-
notype is a significant predictor of CVD in individuals with
DM. Individuals with the Hp 2-2 phenotype had signifi-
cantly higher odds of CVD compared with individuals with
the Hp 2-1 or Hp 1-1 phenotypes. This relationship
persisted after adjustment for known CVD risk factors and
DM characteristics. This study, therefore, suggests that
determination of the haptoglobin phenotype may contribute
to the algorithm used in CVD risk stratification and in the
evaluation of new therapies to prevent CVD in the diabetic
patient. A theranostic application of the knowledge that a
diabetic patient has the Hp 2-2 phenotype would be to
more aggressively manage concomitant cardiovascular risk
factors in such a patient.
Our findings are inconsistent with a recently reported
prospective study from Belgium demonstrating increased car-
diac mortality in patients with the Hp 1-1 phenotype (17).
Three differences between the two studies may explain the
apparently inconsistent results. First, only 7% of the Belgian
cohort had DM as opposed to nearly 60% of the SHS cohort.
The DM subgroup in the Belgian cohort was too small to be
able to determine relative risk by haptoglobin phenotype in
DM. The interaction of DM and haptoglobin phenotype on
risk of CVD is a key finding in our study. Second, the Belgian
study examined a single cardiovascular end point, CVD mor-
tality; our report includes both fatal and nonfatal cardiovascular
events and may, therefore, provide greater insight into the
relationship between haptoglobin and CVD (20). Finally, only
35% of eligible patients were enrolled in the Belgian study (17),
potentially leading to selection bias in that study. In contrast,
the SHS enrollment was approximately twice that of the
Belgian study, suggesting a greater degree of generalizability of
the findings (20). Because our study cohort includes a signif-
icant percentage of individuals of advanced age, we cannot rule
out the effect of selection bias in this study due to survivorship.
Selective mortality may have introduced a bias if DM carriers
of the haptoglobin 1 allele were more likely to die before they
entered the study and could be phenotyped. Thus, DM
patients with Hp 1-1 who were most susceptible to CVD may
have self-selected out of the study due to early mortality. The
Table 1. CVD Risk Factors by Case-Control Status
CVD Risk Factors
Controls Cases
Mean STD Mean STD
Age 59.16 8.01 60.09 8.08
LDL cholesterol 112.1 31.44 123.0 40.47
(Percentile) 25th 50th 75th 25th 50th 75th
Systolic BP (mm Hg) 115 124 137 120 131 148
BMI (kg/m2) 26 30 34 27 30 33
HbA1c (% tot Hb) 4.0 4.0 8.3 4.0 7.2 10.0
Fasting glucose (mg/dl) 100 119 178 110 149 230
Insulin (uU/ml) 9.0 16.0 25.0 11.8 18.7 28.9
HDL (ng/dl) 37 42 52 34 41 49
Triglycerides (ng/dl) 82 119 159 92 134 203
n % n %
Female gender 102 49.51 102 49.51
Diabetes 93 45.15 146 70.87
Current smoker 136 66.02 143 69.42
Family hx DM 131 63.59 145 70.39
Family hx CVD 119 57.77 148 71.84
Center
OK 74 35.92 74 35.92
SD 73 35.44 73 35.44
AZ 59 28.64 59 28.64
The 25th, 50th, and 75th percentiles denote the 1st, 2nd, and 3rd quartile values for that variable (i.e., LDL) present in that
patient group (control or case).
AZ  Arizona; BMI  body mass index; BP  blood pressure; CVD  cardiovascular disease; DM  diabetes mellitus;
HDL  high-density lipoprotein; hx  history of; LDL  low-density lipoprotein; OK  Oklahoma; SD  South Dakota;
STD  standard deviation.
Table 2. Distribution of Hp Types by Case-Control and
Diabetes Status
Hp Type
Cases Controls
n (%) n (%)
DM
1-1 32 (49) 33 (51)
2-1 64 (59) 44 (41)
2-2 50 (76) 16 (24)
Nondiabetic
1-1 9 (26) 25 (74)
2-1 24 (33) 49 (67)
2-2 27 (41) 39 (59)
Note that this was a matched case-control study. Statistical analysis presented in the
manuscript were carried out on matched pairs, and this table ignores matched pairs.
DM  diabetes mellitus; Hp  haptoglobin.
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Belgian study cited above appears to support this idea, but this
is not the case (17). Although the number of DM patients in
the Belgian study was too small to permit meaningful statistical
analysis, the cardiovascular mortality rate in DM patients with
Hp 2-2 or Hp 2-1 was double that in Hp 1-1. Furthermore,
population-based analysis of haptoglobin type stratified by age
has failed to show an increased mortality rate among carriers of
the 1 allele (26).
We cannot rule out the possibility that our findings are
not due to a polymorphism in haptoglobin but rather could
be explained by linkage disequilibrium with another gene
that is in close proximity to the haptoglobin gene. One gene
of interest is the LCAT (lecithin-cholesterol acyl trans-
ferase) gene, which is found in close proximity to the
haptoglobin gene on chromosome 16 (27). Deficiency of the
LCAT gene product, a rare recessive condition, has been
associated with premature atherosclerosis (27). It is impor-
tant to note that our results suggest an association between
functionally distinct phenotypes of the haptoglobin gene
product and CVD. This is distinct from linkage disequilib-
rium, which is the result not only of physical proximity of
loci, but also of many other factors related to the evolution-
ary history of nucleotide diversity in the region. In order for
the association we have reported to reflect an association
based on linkage disequilibrium with LCAT or any other
gene, it would be necessary to define the relevant polymor-
phisms in the LCAT gene and/or establish the pattern of
linkage disequilibrium across the whole region based on the
generation of haplotypes.
Several functions have been assigned to the haptoglobin
protein that may impact on development of atherosclerotic
CVD. It has been appreciated for over 60 years that a major
function of serum haptoglobin is to bind free hemoglobin
(5). This interaction is thought to help scavenge iron, and
prevent its loss in the urine, and to serve as an antioxidant,
thereby protecting tissues against hemoglobin-mediated
tissue oxidation (6). The antioxidant capacity of the differ-
ent haptoglobin phenotypes has been shown to differ, with
the Hp 1-1 protein appearing to confer superior antioxidant
protection as compared with the other forms of the protein
(6,10). Such an antioxidant hypothesis is particularly in-
triguing given the apparent important role of oxidative stress
in the development of diabetic vascular complications (28).
Potentially further amplifying differences in the oxidative
protection afforded by the different types of haptoglobin are
gross differences in the size of the haptoglobin protein
present in individuals with the different phenotypes. Hap-
toglobin 1-1 is markedly smaller than Hp 2-2 and may,
thus, be better able to sieve into the extravascular compart-
ment and prevent hemoglobin-mediated tissue damage at
sites of vascular injury (6). Haptoglobin has also been
demonstrated to play a role as an immunomodulator that
Table 3. Conditional Logistic Regression Predicting the Probability of a CVD Event
Unadjusted Variables OR 95% CI p Value
DM and Hp 2-1 (vs. DM and Hp 1-1) 2.32 (1.27–4.23) 0.006
DM and Hp 2-2 (vs. DM and Hp 1-1) 5.08 (2.37–10.89) 0.001
DM and Hp 2-2 (vs. DM and Hp 2-1) 3.26 (1.67–6.37) 0.001
No DM, Hp 2-1 (vs. no DM, Hp 1-1) 0.63 (0.33–1.20) 0.159
No DM, Hp 2-2 (vs. no DM, Hp 1-1) 1.10 (0.53–2.30) 0.795
No DM, Hp 2-2 (vs. no DM, Hp 2-1) 0.75 (0.40–1.38) 0.350
Adjusted for DM Characteristics Only
Variables OR 95% CI p Value
DM and Hp 2-1 (vs. DM and Hp 1-1) 1.86 (0.93–3.69) 0.078
DM and Hp 2-2 (vs. DM and Hp 1-1) 3.90 (1.68–9.09) 0.002
DM and Hp 2-2 (vs. DM and Hp 2-1) 2.10 (1.00–4.40) 0.049
No DM, Hp 2-1 (vs. no DM, Hp 1-1) 1.40 (0.48–4.09) 0.542
No DM, Hp 2-2 (vs. no DM, Hp 1-1) 2.31 (0.76–7.05) 0.141
No DM, Hp 2-2 (vs. no DM, Hp 2-1) 1.65 (0.73–3.75) 0.228
Adjusted for DM Characteristics and CVD Risk Factors
Variables OR 95% CI p Value
DM and Hp 2-1 (vs. DM and Hp 1-1) 1.63 (0.74–3.63) 0.228
DM and Hp 2-2 (vs. DM and Hp 1-1) 4.96 (1.85–3.33) 0.002
DM and Hp 2-2 (vs. DM and Hp 2-1) 3.04 (1.30–7.09) 0.010
No DM, Hp 2-1 (vs. no DM, Hp 1-1) 1.46 (0.44–4.87) 0.542
No DM, Hp 2-2 (vs. no DM, Hp 1-1) 2.73 (0.81–9.26) 0.107
No DM, Hp 2-2 (vs. no DM, Hp 2-1) 1.88 (0.73–4.80) 0.190
Cases and controls were matched for age, gender, and geographical center. Statistical modeling adjusted for the following DM
characteristics and CVD risk factors. DM characteristics: HbA1c, fasting glucose and insulin, and family history of diabetes.
CVD risk factors: low-density lipoprotein and high-density lipoprotein cholesterol, triglycerides, cigarette use, systolic blood
pressure, body mass index, and family history of CVD.
CI  confidence interval; CVD  cardiovascular disease; DM  diabetes mellitus; Hp  haptoglobin; OR  odds ratio.
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may not be unrelated to its role in hemoglobin metabolism
(6).
The SHS population is a distinct ethnic group with
unique metabolic characteristics associated with a high
degree of obesity and other components of the metabolic
syndrome, including diabetes. However, DM has not been
shown to have unique physiology in American Indians.
Indeed, current American Diabetes Association and WHO
definitions of DM are largely based on data collected in
American Indian communities. The fact that fundamental
clinical practice guidelines are based on data from American
Indians indicates that data from these communities are
generalizable to other populations. In support of the gen-
eralizability of findings in this report are previous studies in
which we demonstrated that the haptoglobin phenotype is
predictive of the development of diabetic microvascular
complications in a Semitic population of diabetics (11–13).
Furthermore, we have recently found in a one-year
follow-up study after coronary artery stent placement of over
900 diabetic patients in Germany that patients with the 1-1
Hp phenotype have significantly less myocardial infarction
and less need for target vessel revascularization as compared
with patients with the Hp 2-1 or Hp 2-2 phenotypes
(Roguin A, Koch W, Kastrati A, Schomig A, Levy AP,
unpublished data). Thus, although the anthropometric and
metabolic profiles of American Indians are unique, the role
of DM in CVD and the potentially modifying role of
haptoglobin in this pathway are similar across ethnicity.
Haptoglobin phenotype appears to be less predictive of
CVD in the non-DM population as compared with the
DM population. This may be due to differences in the
relative importance of antioxidant protection between DM
and non-DM patients. While oxidative modification of
proteins has been implicated in the pathogenesis of athero-
sclerotic disease in the non-DM as well as in the DM
patient, the individual with DM is under considerably more
oxidative stress than the individual without DM (28).
Genetic differences in the endogenous antioxidant status, as
determined by the haptoglobin phenotype, may be, there-
fore, of considerable importance in DM.
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